With a cloud-based update, Medtronic has integrated Artificial Intelligence (AI) into all Reveal LINQ insertable cardiac monitors (ICMs) in the United States, Austria and New Zealand.
In 2014, the business released Reveal LINQ. Users of Reveal LINQ now have access to AccuRhythm AI algorithms, which improve information accuracy and reduce false warnings. The U.S. Food and Drug Administration (FDA) first approved AccuRhythm AI in June 2021 for LINQ II ICMs and in April 2023 for Reveal LINQ ICMs.
According to Medtronic officials, including the algorithms on the ICM should halt and reduce false alarms for atrial fibrillation (AF) by 85%. There should be a 98.2% and 99.9% decrease in true alerts, respectively. The AI technology eliminates a significant portion of false AF and false pause occurrences by applying deep learning algorithms to ICM data entering the CareLink network. Using more than a million ECG cardiac rhythm occurrences from Medtronic, the AI platform and its preliminary algorithms were created.
AccuRhythm AI operates in the cloud autonomously, with no patient interaction. By utilizing deep learning AI algorithms, the platform eliminates a considerable portion of false AF and false pause episodes from the Reveal LINQ ICM data entering the CareLink™ network. Consequently, the workload for clinic reviews is reduced. Medtronic utilized their collection of over a million ECG heart rhythm occurrences to create the AccuRhythm AI platform and its initial algorithms.
“This milestone is both a nod to the past as we celebrate the thousands of patients who have benefited from Reveal LINQ over the last decade and a glimpse into the future as an example of how AI can effectively update an established technology overnight,” said Stacey Churchwell, vice president and general manager of Cardiovascular Diagnostics and Services within Medtronic.
For more details : https://euroinsightscare.com
